Publication:
Novel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris

dc.contributor.authorElgueta, Estefanía
dc.contributor.authorPrieto, Catalina P.
dc.contributor.authorHartmann, Dan
dc.contributor.authorCarrillo, Daniela
dc.contributor.authorEdwards, Natalie
dc.contributor.authorMartínez, Constanza
dc.contributor.authorPérez, Dan
dc.contributor.authorCasas, Bárbara
dc.contributor.authorVergara, Luis
dc.contributor.authorValenzuela, Fernando
dc.contributor.authorCatalán, Verónica
dc.contributor.authorLattus, José
dc.contributor.authorOyarzun-Ampuero, Felipe
dc.contributor.authorPalma, Verónica
dc.date.accessioned2026-07-30T21:19:33Z
dc.date.available2026-07-30T21:19:33Z
dc.date.issued2025
dc.description.abstractBackground Psoriasis vulgaris is the most common form of psoriasis, yet current treatments often lead to significant side effects, resulting in a high rate of therapy desertion. Here, we explored a novel therapeutic approach using the secretome from Wharton Jelly-derived mesenchymal stem cells, biologically stabilized and enhanced with hyaluronic acid (HA), its presentation is an easy-to-apply topical sponge. This formulation had previously demonstrated efficacy in vitro and in experimental psoriasis mouse models. Methods In vitro characterization studies included dynamic light scattering, nanoparticle tracking analysis, optical/electronic microscopy, microbiological experiments, and angiogenic capacity (HUVEC cells). In vivo studies included angiogenic capacity in chicken embryo chorioallantoic membrane (CAM), safety (hypersensitive and healthy volunteers), and efficacy (double-blinded and randomized patients). Results We demonstrated the presence of spherical exosomes (164 ± 87 nm, PDI of 0.38, and 1.5 × 10⁷ particles/mL) within the selected secretomes, which exhibited significant proangiogenic activity in HUVEC cells and in a CAM assay. The secretome-containing sponges displayed distinct physicochemical properties, such as the absence of nitrogen and reduced carbon and oxygen content, resulting in a more cross-linked material with thinner fibers. These characteristics extended the dispersion time in aqueous media. Microbiological testing confirmed sterility in the packed, ready-to-use secretome-HA sponges after 3 months of storage. To assess safety, we selected doses (based on total protein content) that were applied to three patients with atopic dermatitis (42 μg of protein, patch test, 5 days) and four healthy volunteers (210 μg, 15 days) with no observed adverse topical or systemic effects. In a 30-day.
dc.description.versionVersión publicada
dc.format.extent15 p.
dc.identifier.citationElgueta E, Prieto CP, Hartmann D, Carrillo D, Edwards N, Martínez C, Pérez D, Casas B, Vergara L, Valenzuela F, Catalán V, Lattus J, Oyarzun-Ampuero F, Palma V. Novel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris. Stem Cell Res Ther. 2025 Jul 6;16(1):348. doi: 10.1186/s13287-025-04415-1.
dc.identifier.doihttps://doi.org/10.1186/s13287-025-04415-1
dc.identifier.urihttps://hdl.handle.net/11447/10941
dc.language.isoen
dc.titleNovel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceStem Cell Research & Therapy
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s13287-025-04415-1.pdf
Size:
2.65 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description: